Drugs / CAY001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06845839 | Dec 2025 → Oct 2026 expected | — | Cayuga Biotech, Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAY001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06845839 ↗ |
| Route | Intravenous | “Intravenously Administered CAY001” NCT06845839 ↗ |